Literature DB >> 628005

Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.

R K Zee-Cheng, C C Cheng.   

Abstract

A structure-activity relationship study was conducted on a number of bis(substituted aminoalkylamino)anthraquinones. These compounds were prepared by the condensation of substituted or unsubstituted leucoquinizarin with appropriate amines, followed by air oxidation. Both the position and the nature of the center nitrogen atom of the side chain are vital to the antineoplastic activity. The possible mode of action of these aminoquinones was discussed. 1,4-Dihydroxy-5,8-bis[[2-(hydroxyethyl)amino]ethyl]amino-9,10-anthracenedione (DHAQ) was found to possess potent inhibitory activity against both the P-388 leukemia system (T/C of 299 at 0.5 mg/kg with 4/6 cures) and the B-16 melanoma system (T/C of 503 at 1 mg/kg with 7/10 cures).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 628005     DOI: 10.1021/jm00201a012

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  33 in total

Review 1.  Anticancer drug discovery and pharmaceutical chemistry: a history.

Authors:  Miguel F Braña; Ana Sánchez-Migallón
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

2.  The clinical pharmacology of mitozantrone.

Authors:  J F Smyth; J S Macpherson; P S Warrington; R C Leonard; C R Wolf
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Systematic Identification of MCU Modulators by Orthogonal Interspecies Chemical Screening.

Authors:  Daniela M Arduino; Jennifer Wettmarshausen; Horia Vais; Paloma Navas-Navarro; Yiming Cheng; Anja Leimpek; Zhongming Ma; Alba Delrio-Lorenzo; Andrea Giordano; Cecilia Garcia-Perez; Guillaume Médard; Bernhard Kuster; Javier García-Sancho; Dejana Mokranjac; J Kevin Foskett; M Teresa Alonso; Fabiana Perocchi
Journal:  Mol Cell       Date:  2017-08-17       Impact factor: 17.970

4.  Mitoxantrone in malignant lymphoma.

Authors:  R A Gams; S Bryan; G Dukart; A Weiss; D Case; S Jones; R Stein
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Mitoxantrone in refractory acute leukemia in children: a phase I study.

Authors:  K A Starling; A F Mulne; T S Vats; I Schoch; G Dukart
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study.

Authors:  M L Graham; J Estrada; A H Ragab; K A Starling; D Rosen; R W Wilkenson; R W Wilkerson
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

7.  Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system.

Authors:  J D Cowan; D D Von Hoff; G M Clark
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

8.  Investigation of the interaction of cardiotoxic anticancer agents using the fetal mouse heart organ culture system.

Authors:  B F Kimler; R D Rethorst; G G Cox
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

9.  Pharmacology of mitoxantrone in cancer patients.

Authors:  N Savaraj; K Lu; V Manuel; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Structural modification study of anthracyclinones: synthesis and biological activity of several derivatives of eta-pyrromycinone.

Authors:  D F Liu; H Xiong; C C Cheng
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.